<DOC>
	<DOCNO>NCT01226511</DOCNO>
	<brief_summary>The purpose study find duloxetine [ 30-120 milligram ( mg ) ] give day mouth 10 week child adolescent , good placebo treat Generalized Anxiety Disorder ( GAD ) .</brief_summary>
	<brief_title>A Study Pediatric Participants With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Neurotic Disorders</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Diagnosed GAD clinical exam define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) support Mini International Neuropsychiatric Interview child adolescent ( MINIKid ) Diagnosis moderate great severity GAD determine follow : Presence 4 symptom identify generalized anxiety subsection Pediatric Anxiety Rating Scale ( PARS ) symptom checklist screen randomization . Two excessive worry dread fearful anticipation ( nonspecific ) PARS severity score 15 screen randomization symptom identify generalized anxiety subsection PARS symptom checklist screen randomization Clinical Global Impressions Severity ( CGIS ) rating 4 screen randomization Presence significant social , academic , and/or familial dysfunction determine Children 's Global Assessment Scale ( CGAS ) score 60 less screen randomization Female participant must test negative pregnancy screen Furthermore , female participant must agree abstain sexual activity use reliable method birth control determine investigator study Participant 's parent/legal representative participant , capable , judge reliable investigator keep appointment clinical visit , test , procedure require protocol Participant 's parent/legal representative participant , capable , must degree understand communicate intelligently investigator study coordinator Participants must capable swallow study drug whole ( without open capsule , crush , dissolve , divide , et cetera ) Participants must venous access sufficient allow blood sample compliant blood draw per protocol Current diagnosis major depressive disorder ( MDD ) Participants primary focus treatment separation anxiety social phobia ( participant secondary separation anxiety social phobia allow participate ) Have current primary diagnosis DSMIVTR Axis I disorder except GAD , current secondary DSMIVTR Axis 1 disorder require pharmacologic treatment ( disorder list ) . Primary define disorder primary focus treatment Have history DSMIVTRdefined substance abuse dependence within past year , exclude caffeine nicotine Have current previous diagnosis bipolar disorder , psychotic depression , schizophrenia psychotic disorder , anorexia , bulimia , obsessive compulsive disorder , posttraumatic stress disorder , panic disorder , pervasive development disorder , judge investigator Have 1 firstdegree relative ( parent sibling ) diagnose bipolar I disorder Have serious unstable medical illness , psychological condition , clinically significant laboratory electrocardiogram ( ECG ) result , hypersensitivity duloxetine , active ingredient , frequent severe allergic reaction multiple medication , uncontrolled narrowangle glaucoma , acute liver injury ( example , hepatitis ) severe cirrhosis ( ChildPugh Class C ) , history seizure disorder ( febrile seizure ) Have significant suicide attempt within 1 year screen currently risk suicide opinion investigator Have initiate , stop , change type intensity psychotherapy within 6 week prior screen . Participants require change psychotherapy week 1 10 exclude Have weight less 20 kilogram time screen period Female participant pregnant , nurse recently give birth</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>